The ability to unfold a protein and return it to its original state could save money in everything from cancer research to food production.» Read More
Pharmaceutical giant Bristol-Myers Squibb named Dr. Giovanni Caforio as its new CEO on Tuesday.
Discussing the current state of Europe at Davos 2015, Karl-Ludwig Kley, chairman of Merck says the lack of coordination and cohesion in European businesses is the current problem.Meanwhile political leaders need a wake-up call.
CNBC's Meg Tirrell and Leonard Schleifer, Regeneron president & CEO, talk about providing fair drug pricing for patients.
The Justice Department kept a secret database of incoming and outgoing U.S. international calls for more than a decade.
Johnson & Johnson said that newly formed groups supporting work on its experimental Ebola vaccine would receive $115 million to speed development.
Biotech stocks in the U.S. have outperformed significantly over the last three years -- and this can continue, says Matthew Roden, executive director of biotechnology equity research at UBS AG.
More than three-quarters of Americans who got this season's flu shot could get the virus anyway.
Scientists have developed a glucose monitor that is about as invasive as a rub-on tattoo.
Healthcare executives talk about their weekend activities.
Healthcare industry executives name the CEOs they'd be most willing to trade places with.
Biopharma executives at the J.P. Morgan Healthcare Conference talk about this year's biggest challenges.
Louis Navellier says crunching the numbers for stocks that move independent of the market point him to two drug companies and a Chinese retailer.
U.S. companies are increasingly penalizing workers who decline to join "wellness" programs.
Michelle Berrey, Chimerix CEO, discusses the testing of its Ebola drug Brincidofovir in a clinical setting in West Africa, with CNBC's Meg Tirrell.
"Any event in life changes one. That was an event that probably changed me in many ways. I think I am a better person," biotech company founder Sam Waksal.
Get the best of CNBC in your inbox